181 related articles for article (PubMed ID: 37389736)
1. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
[TBL] [Abstract][Full Text] [Related]
2. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
4. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
[TBL] [Abstract][Full Text] [Related]
5. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
6. Identifying Optimal Candidates for Trimodality Therapy among Nonmetastatic Muscle-Invasive Bladder Cancer Patients.
Ran S; Yang J; Hu J; Fang L; He W
Curr Oncol; 2023 Nov; 30(12):10166-10178. PubMed ID: 38132374
[TBL] [Abstract][Full Text] [Related]
7. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
8. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
[TBL] [Abstract][Full Text] [Related]
9. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
10. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
[TBL] [Abstract][Full Text] [Related]
11. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
Reignier PL; Gauthier H; Hennequin C; Aussedat Q; Xylinas E; Desgrandchamps F; Culine S; Masson-Lecomte A; Dumont C
World J Urol; 2023 Nov; 41(11):3249-3255. PubMed ID: 37410102
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
13. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
Su X; Dong C; Liao W; Liu W
World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
[TBL] [Abstract][Full Text] [Related]
14. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
[TBL] [Abstract][Full Text] [Related]
15. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
16. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
17. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Francolini G; Borghesi S; Fersino S; Magli A; Jereczek-Fossa BA; Cristinelli L; Rizzo M; Corvò R; Pappagallo GL; Arcangeli S; Magrini SM; D'Angelillo RM
Crit Rev Oncol Hematol; 2021 Mar; 159():103235. PubMed ID: 33493633
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
Yao Z; Jiang Y; Zhu X; Wu B; Bai S
Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
20. Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study.
Lai S; Liu J; Lai CH; Seery S; Hu H; Wang M; Hu H; Xu T
Int J Surg; 2024 Jan; 110(1):270-279. PubMed ID: 37738002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
